Friday, 16 October 2026European Markets

BOUVET And NEURONES Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - bouvet (bouv.ol) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
bouvet (bouv.ol) kr58.10 4.08% 60.9%
neurones (nro.pa) €37.15 2.97% 15.36%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. bouvet (bouv.ol)

4.08% forward dividend yield and 60.9% return on equity

bouvet asa provides it and digital communication consultancy services for public and private sector companies in norway, sweden, and internationally. bouvet asa was founded in 1995 and is based in oslo, norway.

earnings per share

as for profitability, bouvet has a trailing twelve months eps of kr3.15.

pe ratio

bouvet has a trailing twelve months price to earnings ratio of 18.44. meaning, the purchaser of the share is investing kr18.44 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 60.9%.

revenue growth

year-on-year quarterly revenue growth grew by 16.5%, now sitting on 3.22b for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, bouvet's stock is considered to be oversold (<=20).

volume

today's last reported volume for bouvet is 14463 which is 65.43% below its average volume of 41842.

more news about bouvet.

2. neurones (nro.pa)

2.97% forward dividend yield and 15.36% return on equity

neurones s.a., an information technology (it) services company, provides infrastructure, application, and consulting services in france and internationally. its infrastructure services include infrastructure management, manages public and private cloud services, it operations, user support, devops, cybersecurity, it service management, information system governance, and automation. the company also provides application services in the areas of sap, digital, web, mobility, ux/ui, enterprise content and document management, business process management, robotic process automation, dematerialization, it consulting for finance, big data, and devops, it training and change management, and innovation connected devices (iot). in addition, it offers consulting services, including management and digital transformation, and digital marketing consulting; digital transformation services in the areas of agile/scrum, devops, ci/cd, cloud, infrastructure as code, cyber security, analytics, big data, mobility, digital workplace, connected devices, innovations, client experience, ux/ui, and digital marketing, as well as internal process digitization, ecm/bpm, rpa, dematerialization, ai, predictive maintenance, machine learning, and blockchain; and managed services/outsourcing services. the company serves banking/insurance, services/consumer goods, energy/utilities/healthcare, technologies/media/telecoms, industry/public works and civil engineering, and public sector markets. neurones s.a. was founded in 1984 and is based in nanterre, france.

earnings per share

as for profitability, neurones has a trailing twelve months eps of €1.96.

pe ratio

neurones has a trailing twelve months price to earnings ratio of 18.95. meaning, the purchaser of the share is investing €18.95 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.36%.

volume

today's last reported volume for neurones is 773 which is 80.31% below its average volume of 3926.

yearly top and bottom value

neurones's stock is valued at €37.15 at 11:30 est, way under its 52-week high of €44.00 and way higher than its 52-week low of €33.45.

revenue growth

year-on-year quarterly revenue growth grew by 12.7%, now sitting on 706.93m for the twelve trailing months.

more news about neurones.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com